Study of JAB-21822 Monotherapy in Advanced Pancreatic Cancer and Other Solid Tumors with KRAS p.G12C Mutation An Open-label Phase II Clinical Trial

What this Trial Is About

This research investigates the use of JAB-21822 (Glecirasib) as a treatment for adult patients with locally advanced or metastatic solid tumors that have the KRAS p.G12C mutation. The trial focuses on patients with pancreatic cancer who have not responded to or cannot tolerate specific chemotherapy regimens, as well as patients with other advanced solid tumors excluding non-small cell lung cancer and colorectal cancer. The study aims to evaluate the effectiveness and safety of this drug in these groups. Participants receive JAB-21822 orally at a dose of 800 mg once daily in 21-day cycles. Treatment continues until the disease progresses, intolerable side effects occur, or participants choose to withdraw. This is a single-arm, open-label phase II trial conducted at multiple centers, meaning all participants receive the same experimental treatment without a comparison group. Throughout the trial, researchers monitor participants for their response to treatment using imaging reviewed by an independent radiology committee over approximately 1.5 years. They track the objective response rate, safety, and tolerability. The study includes regular assessments and follows patients until disease progression or other reasons for stopping treatment, aiming to gather detailed information on how well the drug works and its side effects.

A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.